Kanada - angleščina - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 200mg - cyclophosphamide 200mg - antineoplastic agents

Kanada - angleščina - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 500mg - cyclophosphamide 500mg - antineoplastic agents

Kanada - angleščina - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 1000mg - cyclophosphamide 1000mg - antineoplastic agents

Kanada - angleščina - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 2000mg - cyclophosphamide 2000mg - antineoplastic agents

Irska - angleščina - HPRA (Health Products Regulatory Authority)

asta medica ltd - cyclophosphamide - pdr for soln for injection - 100 milligram

Irska - angleščina - HPRA (Health Products Regulatory Authority)

asta medica ltd - cyclophosphamide - pdr for soln for injection - 100 milligram

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide -

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 1069mg equivalent to cyclophosphamide anhydrous 1000 mg;   - powder for injection - 1000 mg - active: cyclophosphamide monohydrate 1069mg equivalent to cyclophosphamide anhydrous 1000 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg;   - powder for injection - 2000 mg - active: cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 534.5mg equivalent to cyclophosphamide anhydrous 500 mg;   - powder for injection - 500 mg - active: cyclophosphamide monohydrate 534.5mg equivalent to cyclophosphamide anhydrous 500 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.